NeOnc Strengthens Boardroom Firepower as Abu Dhabi Opens a New Path for Brain Cancer Drug Development
Key Highlights
- ➤NEO100 Phase 2a: six-month progression-free survival reached 48.9%
- ➤NEO100 Phase 2a median overall survival reached 26.09 months
- ➤NEO212 completed Phase 1 dose escalation, advancing toward Phase 2
- ➤Abu Dhabi authorized NEO212 investigational new drug development, pending ethics approvals
- ➤FDA End-of-Phase 1 Type B meeting for NEO212 set for November 17, 2026
Expert Statements
Amir Heshmatpour, Executive Chairman, President and Chief Executive Officer of NeOnc Technologies Holdings
“Ali’s appointment strengthens our Board as we advance our clinical programs and build our presence in Abu Dhabi”
DENVER, Oct. 14, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- NeOnc Technologies Holdings (NASDAQ:NTHI) is strengthening its boardroom, while its clinical-development progress seeks to advance treatments for some of the most difficult cancers to treat. The clinical-stage biopharmaceutical company appointed Ali Alabedin, Head of Islamic Banking Group at First Abu Dhabi Bank, to its Board of Directors effective October 9, 2026, adding more than three decades of international banking, governance and business leadership experience.
“Ali’s appointment strengthens our Board as we advance our clinical programs and build our presence in Abu Dhabi,” said Amir Heshmatpour, NeOnc’s executive chairman, president and chief executive officer. Alabedin succeeds Dr. Steven L. Giannotta, who has stepped down from the board but will continue serving on NeOnc’s Scientific Advisory Board, preserving his scientific contribution while the company adds financial and international-growth expertise.
Get started
Create a free account to read the full story.